Biotech dealmaking surged this week, from Pfizer’s $7.3 billion obesity acquisition to a run of licensing, royalty financings, and venture rounds. Disclosed upfronts exceeded $6 billion, with total potential deal values over $9 billion. The week highlights two trends: Big Pharma securing pipelines in obesity, CNS, and AI-driven drug design; and smaller players stretching cash with royalty monetizations and venture top-ups.

Biotech Dealmaking Week: September 22-28, 2025

Biotech dealmaking surged this week, from Pfizer's $7.3 billion obesity acquisition to a run of licensing, royalty financings, and venture rounds. Disclosed upfronts exceeded $6 billion, with total potential deal values over $9 billion. The week highlights two trends: Big Pharma securing pipelines in obesity, CNS, and AI-driven drug design; and smaller players stretching cash with royalty monetizations and venture top-ups.

Mergers & Acquisitions

Pfizer acquires Metsera – Up to $7.3B

Terms: $47.50/share cash (~$4.9B upfront) plus CVRs up to $22.50/share tied to milestones (total $7.3B).
Assets: MET-097i (Phase 2b long-acting GLP-1 agonist), MET-233i (Phase 1 monthly amylin analog), oral GLP-1 candidates (preclinical/early clinical).
Clinical detail: MET-097i is in a Phase 2 obesity trial testing monthly vs weekly dosing; MET-233i is a Phase 1 amylin analog tested alone and in combination. Both showed promising efficacy/tolerability in early studies.
Rationale: Pfizer rebuilds its obesity pipeline after failures in oral GLP-1.
Advisors: Pfizer: Citi (financial), Wachtell Lipton (legal). Metsera: Goldman Sachs, Guggenheim, BofA, Allen & Co. (financial); Paul Weiss (legal).

CB Biotechnology completes Theratechnologies acquisition – $254M EV

Terms: $3.01/share cash + CVRs up to $1.19/share tied to revenues from Egrifta and Trogarzo. Total EV up to ~$254M.
Assets: FDA-approved HIV products – Egrifta SV (tesamorelin for HIV lipodystrophy) and Trogarzo (ibalizumab-uiyk for multidrug-resistant HIV-1).
Clinical detail: Egrifta SV reduces visceral adipose tissue in HIV lipodystrophy; Trogarzo is used IV in heavily treatment-experienced HIV patients with resistant virus.
Rationale: Future Pak secures revenue-generating assets; Theratech exits strained capital markets.
Advisors: Theratech: Barclays (FA), Raymond James (independent FA), Fasken (legal), Norton Rose (legal). CB Biotech: Bourne Partners (FA), Honigman & McMillan (legal), DPO&Co (transaction advisor).

(CVRs—contingent value rights—are milestone-tied instruments giving shareholders potential future payouts, often used to bridge valuation gaps.)

Royalty & Structured Financings

Arecor & Ligand – $11M royalty monetization

Terms: $7M upfront + $4M milestone. Ligand acquires royalties/fees from Arecor's AT220 (partnered biosimilar) and AT292 (Phase 2 alpha-1 antitrypsin deficiency program), plus 10-year warrants for ~1M Arecor shares.
Rationale: Extends Arecor's runway into 2027 to advance AT278 insulin; Ligand secures annuity-like revenue with equity upside.
Advisors: Structured as a bilateral transaction; no external FA disclosed.

Licensing & Partnerships

Angelini & Sovargen – $550M antisense option

Asset: SVG105, a preclinical antisense oligonucleotide targeting mTOR for drug-resistant epilepsy.
Clinical detail: Preclinical studies target refractory childhood epilepsies; designed to reduce aberrant mTOR activity driving seizures.
Terms: Upfront undisclosed + up to $550M milestones + royalties. Rights ex-Asia.
Rationale: Angelini deepens CNS pipeline; Sovargen gains global partner.

Starpharma & Genentech – $564M DEP® license

Asset: DEP® dendrimer delivery tech for oncology.
Clinical detail: Starpharma's DEP-docetaxel and DEP-cabazitaxel showed improved solubility and reduced toxicity in Phase 2 oncology trials. Genentech to apply DEP to its own drugs.
Terms: $5.5M upfront + $564M milestones + royalties.
Rationale: Improves delivery profile of Genentech's oncology pipeline.

Hengrui & Glenmark – $1.09B HER2 ADC license

Asset: Trastuzumab rezetecan (SHR-A1811), a HER2 ADC.
Clinical detail: Approved in China for HER2-mutant NSCLC; in trials for HER2+ breast, gastric, colorectal, biliary cancers. Payload delivers a bystander effect, expanding efficacy.
Terms: $18M upfront + up to $1.09B milestones + royalties. Rights ex-China/US/EU/Japan.
Rationale: Glenmark builds oncology portfolio in emerging markets; Hengrui monetizes ex-China rights.

Lantheus & GE Healthcare – Pylarify in Japan

Asset: Pylarify (piflufolastat F-18), PSMA-targeted PET tracer.
Clinical detail: FDA-approved 2021, widely used for prostate cancer staging and recurrence monitoring. 500k+ scans to date in US.
Terms: Upfront + milestones + royalties (undisclosed).
Rationale: GE leverages Nihon Medi-Physics for Japanese commercialization.

Merck & Variational AI – $349M AI small-molecule design

Asset: AI-designed small molecules for 2 Merck targets.
Clinical detail: Discovery stage; Variational's Enki platform generated hits that met Merck's target product profiles in pilot.
Terms: Upfront undisclosed; up to $349M milestones.
Rationale: Merck expands AI efforts for undruggable targets.

Merck & Evaxion – $592M AI vaccine

Asset: EVX-B3, preclinical AI-designed vaccine for recurrent pathogen.
Clinical detail: No vaccine currently exists; Evaxion's AI-Immunology identified novel antigen targets.
Terms: $7.5M upfront; up to $592M milestones + royalties.
Rationale: Merck expands early vaccines; validates Evaxion's AI platform.

Solid Biosciences & Kinea Bio – AAV capsid license

Asset: AAV-SLB101 capsid for KNA-155 gene therapy.
Clinical detail: KNA-155 is a dual-vector AAV for dysferlinopathy (LGMD2B/R2); IND-enabling. Capsid improves skeletal muscle targeting.
Terms: Upfront + milestones + royalties (undisclosed).
Rationale: Solid monetizes enabling tech; Kinea accelerates LGMD2B therapy.

Venture Financings

Sparrow Pharmaceuticals – $95M Series B

Asset: Clofutriben (oral 11β-HSD1 inhibitor).
Clinical detail: In Phase 2b CAPTAIN-T2D trial in T2D patients with hypercortisolism; placebo-controlled, HbA1c change as primary endpoint.
Investors: Co-led by RA Capital, Forbion; joined by OrbiMed, RiverVest, USVP.

Avenzo Therapeutics – $60M Series B

Pipeline: AVZO-021 (Phase 1/2 CDK2 inhibitor for breast cancer), AVZO-023 (CDK4 inhibitor), AVZO-1418 (Phase 1/2 bispecific ADC), preclinical ADC option.
Investors: Led by OrbiMed, SR One; Longwood, Foresite, Lilly Asia Ventures, NEA, Sofinnova, others.

Until Labs – $58M Series A

Asset: Organ cryopreservation platform.
Investors: Led by Founders Fund; Lux Capital, Field Ventures joined.

Ensoma Bio – $53M financing

Asset: EN-374, in vivo HSC-directed gene therapy for X-CGD.
Clinical detail: Phase 1/2 open-label, single ascending dose; endpoint is neutrophil oxidative burst activity.
Investors: Syndicate including Gilead, Viking, Gates Foundation, RTW, QIA, 5AM, SymBiosis.

Rapid Micro Biosystems – $45M growth equity

Asset: Growth Direct® platform for automated microbial QC.
Financier: Trinity Capital provided term loan facility.

Public Financings

Eupraxia Pharmaceuticals – $80.5M follow-on

Asset: EP-104IAR (extended-release fluticasone for knee OA, Phase 3-ready) and EP-104GI (EoE, Phase 1/2).
Financiers: Public equity investors via follow-on.

Soligenix – $7.5M public offering

Assets: HyBryte (SGX301, photodynamic therapy for CTCL, Phase 3 completed); SGX942 (oral mucositis, mixed Phase 3 data).
Financiers: Public equity + warrants offering.

Venture Capital & Fund Initiatives

Sanofi Ventures – $625M new commitment

Mandate: Immunology, neurology, rare disease, vaccines, longevity, pain.
Funders: Backed directly by Sanofi; evergreen reinvestment model.

Government & Infrastructure

Amgen – $650M Puerto Rico expansion

Adds biologics capacity, 750 jobs; aligns with U.S. onshoring initiatives.

Basilea – BARDA contract up to $159M

Funds Phase 3 for oral antibiotic ceftibuten-ledaborbactam for cUTI.

Maine Life Sciences Center – $2.7M state grants

Funds biotech incubator and shared labs in Portland.